Track Skye Bioscience, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Skye Bioscience, Inc. SKYE Open Skye Bioscience, Inc. in new tab

0.6980 USD
EPS
-1.41
P/B
0.96
ROE
-126.85
Beta
2.86
Target Price
8.25 USD
Skye Bioscience, Inc. logo

Skye Bioscience, Inc.

🧾 Earnings Recap – Q3 2025

Skye Bioscience, Inc. delivered promising data from its Phase 2a CBEYOND study, demonstrating strong efficacy of Nimazumab in combination with semaglutide and reporting a net loss of $12.8 million for Q3 2025.

  • Cash reserves stood at $35.3 million, expected to fund operations through 2027.
  • R&D expenses rose to $9.4 million, reflecting increased clinical trial activity and manufacturing costs.
  • Positive findings from the CBEYOND study revealed a 30% improvement in weight loss efficacy when combining Nimazumab with semaglutide.
  • Data also demonstrated enhanced metabolic benefits and safety with no significant adverse effects observed.
  • Enrollment in a 26-week extension study was completed, with results anticipated by late Q1 2026.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 7, 2026
EPS-1.41
Book Value0.60
Price to Book0.96
Debt/Equity1.37
% Insiders1.339%
Estimates
Forward P/E-0.54
Forward EPS-1.07
Target Mean Price8.25

DCF Valuation

Tweak assumptions to recompute fair value for Skye Bioscience, Inc. (SKYE)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Skye Bioscience, Inc. Logo Skye Bioscience, Inc. Analysis (SKYE)

United States Health Care Official Website Stock

Is Skye Bioscience, Inc. a good investment? Skye Bioscience, Inc. (SKYE) is currently trading at 0.6980 USD. Market analysts have a consensus price target of 8.25 USD. This suggests a potential upside from current levels.

Earnings Schedule: Skye Bioscience, Inc. is expected to release its next earnings report on May 7, 2026. The market consensus estimate for Forward EPS is -1.07.

Investor FAQ

Does Skye Bioscience, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Skye Bioscience, Inc.?

Skye Bioscience, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 7, 2026. The company currently has a trailing EPS of -1.41.

Company Profile

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.

Exchange Ticker
PNK (United States) SKYE

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Sept. 8, 2023 0.000000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion